Neurodegenerative brain disease and trauma affect over 35 million patients worldwide, accounting for over $1.3 trillion of nondiscretionary healthcare spending every year.
Our technology offers a novel approach (single cell analysis vs serum), a simple, minimally invasive (small amounts of blood), and significantly cheaper (than existing) assay system to enable breakthrough discoveries in research, drug development and patient care.
ZelosDx’s mission is to make the WINDOW INTO THE BRAIN (TM) novel blood-testing tool widely available to researchers that have expressed an interest in investigating neurologic processes at the cellular level. At launch, the company will offer our customers these blood tests as a Research use only (RUO) service. A researcher can send their animal or human blood samples directly to ZelosDx for testing. The company plans to launch this service offering in 2022.
Researchers can send their animal or human blood samples directly to ZelosDx for testing.
The most efficient approach to reach the research market is to license the patented ZelosDx technology to manufactures for incorporation into their blood testing portfolio. This includes kits for ELISA as well as cell-based assays.
Copyright © 2021 ZelosDx - All Rights Reserved.